Pharming Group N.V. (PHGUF)
USD 0.9
(0.0%)
USD 0.9
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 462.85 Million USD | 8.7% |
| 2022 | 425.79 Million USD | 7.28% |
| 2021 | 396.9 Million EUR | -5.3% |
| 2020 | 419.11 Million EUR | 63.95% |
| 2019 | 255.63 Million EUR | 0.0% |
| 2018 | - USD | -100.0% |
| 2017 | 199.37 Million EUR | 49.53% |
| 2016 | 133.33 Million EUR | 111.45% |
| 2015 | 63.05 Million EUR | -6.93% |
| 2014 | 67.75 Million EUR | 56.22% |
| 2013 | 43.37 Million EUR | 94.69% |
| 2012 | 22.27 Million EUR | -30.4% |
| 2011 | 32 Million EUR | -35.46% |
| 2010 | 49.59 Million EUR | -38.06% |
| 2009 | 80.06 Million EUR | -28.76% |
| 2008 | 112.39 Million EUR | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 104.36 Million EUR | 154.78% |
| 2005 | 40.96 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 415.68 Million USD | -5.8% |
| 2024 Q3 | 425.51 Million USD | 2.36% |
| 2024 Q1 | 441.25 Million USD | -6.23% |
| 2023 Q1 | 422.99 Million USD | -0.66% |
| 2023 Q3 | 436.46 Million USD | 1.55% |
| 2023 Q2 | 429.8 Million USD | 1.61% |
| 2023 FY | 462.85 Million USD | 8.7% |
| 2023 Q4 | 470.56 Million USD | 7.81% |
| 2022 Q3 | 382.32 Million USD | -2.94% |
| 2022 Q4 | 425.79 Million USD | 11.37% |
| 2022 FY | 425.79 Million USD | 7.28% |
| 2022 Q1 | 392.79 Million USD | -2.51% |
| 2022 Q2 | 393.89 Million USD | 0.28% |
| 2021 Q2 | 411.84 Million EUR | 0.62% |
| 2021 Q3 | 400.6 Million EUR | -2.73% |
| 2021 Q4 | 402.92 Million EUR | 0.58% |
| 2021 FY | 396.9 Million EUR | -5.3% |
| 2021 Q1 | 409.29 Million EUR | -2.19% |
| 2020 Q1 | 335.22 Million EUR | 30.99% |
| 2020 FY | 419.11 Million EUR | 63.95% |
| 2020 Q4 | 418.45 Million EUR | 11.61% |
| 2020 Q3 | 374.93 Million EUR | 5.13% |
| 2020 Q2 | 356.64 Million EUR | 6.39% |
| 2019 Q4 | 255.91 Million EUR | 5.93% |
| 2019 Q1 | 224.1 Million EUR | -8.79% |
| 2019 Q2 | 233.98 Million EUR | 4.41% |
| 2019 FY | 255.63 Million EUR | 0.0% |
| 2019 Q3 | 241.59 Million EUR | 3.25% |
| 2018 Q3 | 223.93 Million EUR | 6.79% |
| 2018 FY | - USD | -100.0% |
| 2018 Q4 | 245.71 Million USD | 9.72% |
| 2018 Q2 | 209.69 Million EUR | -0.35% |
| 2018 Q1 | 210.43 Million EUR | 5.54% |
| 2017 Q1 | 140.45 Million EUR | 5.34% |
| 2017 FY | 199.37 Million EUR | 49.53% |
| 2017 Q4 | 199.37 Million EUR | 21.33% |
| 2017 Q3 | 164.33 Million EUR | 13.14% |
| 2017 Q2 | 145.24 Million EUR | 3.41% |
| 2016 Q3 | 54.81 Million EUR | -8.18% |
| 2016 Q1 | 63.2 Million EUR | 0.24% |
| 2016 Q2 | 59.69 Million EUR | -5.56% |
| 2016 Q4 | 133.33 Million EUR | 143.27% |
| 2016 FY | 133.33 Million EUR | 111.45% |
| 2015 FY | 63.05 Million EUR | -6.93% |
| 2015 Q3 | 69.94 Million EUR | 24.32% |
| 2015 Q4 | 63.05 Million EUR | -9.84% |
| 2015 Q2 | 56.25 Million EUR | -3.35% |
| 2015 Q1 | 58.2 Million EUR | -14.09% |
| 2014 FY | 67.75 Million EUR | 56.22% |
| 2014 Q4 | 67.75 Million EUR | 30.99% |
| 2014 Q3 | 51.72 Million EUR | -7.52% |
| 2014 Q2 | 55.92 Million EUR | 22.47% |
| 2014 Q1 | 45.66 Million EUR | 5.29% |
| 2013 Q2 | 37.36 Million EUR | -0.71% |
| 2013 Q4 | 43.37 Million EUR | 35.51% |
| 2013 FY | 43.37 Million EUR | 94.69% |
| 2013 Q3 | 32 Million EUR | -14.35% |
| 2013 Q1 | 37.63 Million EUR | 68.94% |
| 2012 Q3 | 20.09 Million EUR | 0.0% |
| 2012 Q1 | 36.95 Million EUR | 15.45% |
| 2012 Q4 | 22.27 Million EUR | 10.86% |
| 2012 FY | 22.27 Million EUR | -30.4% |
| 2011 FY | 32 Million EUR | -35.46% |
| 2011 Q3 | 37.68 Million EUR | -12.62% |
| 2011 Q1 | 46.4 Million EUR | -6.43% |
| 2011 Q2 | 43.12 Million EUR | -7.06% |
| 2011 Q4 | 32 Million EUR | -15.07% |
| 2010 Q2 | 87.86 Million EUR | 6.59% |
| 2010 FY | 49.59 Million EUR | -38.06% |
| 2010 Q1 | 82.43 Million EUR | 2.96% |
| 2010 Q4 | 49.59 Million EUR | -33.05% |
| 2010 Q3 | 74.07 Million EUR | -15.7% |
| 2009 FY | 80.06 Million EUR | -28.76% |
| 2009 Q4 | 80.06 Million EUR | 0.0% |
| 2008 FY | 112.39 Million EUR | 0.0% |
| 2007 FY | - USD | -100.0% |
| 2006 FY | 104.36 Million EUR | 154.78% |
| 2005 FY | 40.96 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -20036869.697% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -23536.84% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -4285.579% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -83732.138% |
| Rebus Holdings, Inc. | 5000.00 USD | -9256980.0% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -255.465% |
| Qrons Inc. | 420.00 USD | -110203233.333% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -59960.677% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -1556.363% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -96216.15% |
| Skye Bioscience, Inc. | 11.94 Million USD | -3776.366% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -1091.479% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -6310.932% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -606094.829% |
| SQZ Biotechnologies Company | 107.18 Million USD | -331.819% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -32221.484% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -639510.309% |
| Mesoblast Limited | 667.9 Million USD | 30.7% |
| Marizyme, Inc. | 22.01 Million USD | -2002.441% |
| Genus plc | 1.02 Billion USD | 55.015% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -33974.648% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -13870.792% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -92649.064% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -73720.415% |
| ContraFect Corporation | 20.67 Million USD | -2138.28% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -118469.24% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -121009.852% |
| IMV Inc. | 31.33 Million USD | -1377.172% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -11063.81% |
| MultiCell Technologies, Inc. | 126.22 USD | -366704067.327% |
| ONE Bio Corp. | 70.08 Million USD | -560.413% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -49156.084% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -260.17% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -107113.109% |
| Q BioMed Inc. | 3.51 Million USD | -13066.029% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -1215.711% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -177050.687% |
| Biomind Labs Inc. | 73.81 Thousand USD | -626912.016% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | -3.707% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -31846.457% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -1442.078% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -16753.516% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -67225.589% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -17680.221% |
| GB Sciences, Inc. | 103.44 Thousand USD | -447352.679% |
| Alpha Cognition Inc. | 2.45 Million USD | -18775.282% |
| HST Global, Inc. | 1526.00 USD | -30331092.661% |
| CSL Limited | 38.02 Billion USD | 98.783% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -46749.136% |
| Halberd Corporation | 10.13 Thousand USD | -4568590.159% |
| Enzolytics Inc. | 361.7 Million USD | -27.964% |
| Agentix Corp. | 261.39 Thousand USD | -176972.749% |
| Resverlogix Corp. | 8.11 Million USD | -5603.685% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -24547.688% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 89.81% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -870.303% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -72259.831% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -2031654.532% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -5072.041% |
| AVAX Technologies, Inc. | 7.37 Million USD | -6174.151% |
| Zenith Capital Corp. | 7410.00 USD | -6246242.78% |
| Genscript Biotech Corporation | 3.38 Billion USD | 86.332% |
| Ember Therapeutics, Inc. | 184.00 USD | -251550986.957% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -143730.134% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -176991.719% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -49778.605% |
| Kadimastem Ltd | 2.3 Million USD | -19988.452% |
| Helix BioMedix, Inc. | 3.02 Million USD | -15200.524% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -778.264% |
| BioStem Technologies, Inc. | 14.56 Million USD | -3078.879% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -810587.638% |
| LadRx Corporation | 2.3 Million USD | -19955.358% |
| Cell Source, Inc. | 195.17 Thousand USD | -237053.061% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -130791.332% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -130791.332% |
| NovAccess Global Inc. | 62.24 Thousand USD | -743464.452% |
| Affymax, Inc. | 7.44 Million USD | -6118.648% |
| Itoco Inc. | 1.4 Million USD | -32959.3% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -483768.405% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -436554.717% |
| Mobile Lads Corp. | 52.00 USD | -890103746.154% |
| CytoDyn Inc. | 11.13 Million USD | -4056.376% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -323637.515% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -2588568.904% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -119974.921% |
| SYBLEU INC | 330.46 Thousand USD | -139960.157% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -112950.593% |
| International Stem Cell Corporation | 5.39 Million USD | -8487.273% |
| Bioxytran, Inc. | 137.63 Thousand USD | -336183.584% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -2985.317% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -2691.809% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -585791.139% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -53429.121% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -6057.43% |
| Neutra Corp. | 2851.00 USD | -16234694.809% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -1328.297% |
| PureTech Health plc | 693.97 Million USD | 33.304% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -5634.716% |
| IXICO plc | 15.84 Million USD | -2821.338% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -5488.674% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -347.964% |
| CSL Limited | 38.02 Billion USD | 98.783% |
| Cellectis S.A. | 333.99 Million USD | -38.581% |